title: Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity.
abstract: Impaired cell-mediated immunity predisposes individuals to severe systemic HSV infections. A potential approach for enhancing antiviral immunity is to alter the specificity of T cells and NK cells so that they become cytotoxic against HSV. We describe here the use of heteroconjugate antibodies to augment the killing of HSV-infected cells. Two different types of heteroconjugate antibodies were used: 1) CD3-specific mAb, covalently linked to HSV-specific mAb (e.g., anti-CD3 x anti-HSV-1 glycoprotein C); 2) FcR-specific mAb linked to HSV-specific mAb (e.g., anti-Fc gamma RIII x anti-HSV-1 glycoprotein D). Whereas freshly isolated, PBL were not cytotoxic against HSV-infected target cells in a 5-h 51Cr-release assay, co-incubation with either heteroconjugate resulted in significant cytotoxicity. In vitro activated PBL (anti-CD3 + IL-2) also became more potent killers of HSV-infected cells in the presence of each heteroconjugate. The specificity of anti-CD3 x anti-HSV-1 and anti-Fc gamma RIII x anti-HSV-1 gD for enhancing T cell and NK cell immunity, respectively, was confirmed by using cloned, homogeneous human T cell and NK cell lines as effectors. Kinetic analysis demonstrated that as soon as the infected cells began to express HSV glycoproteins on their surface they became susceptible to this enhanced killing. Prolonged culture of HSV-infected cells with heteroconjugate antibodies and effector cells also decreased the amount of viral replication that occurred, as measured in a plaque inhibition assay. These results suggest that heteroconjugate antibodies are potent immunotherapeutic tools that enhance anti-HSV immunity.
authors.affiliation: Division of Infectious Disease, Mayo Clinic and Foundation, Rochester, MN 55905.
authors.forename: C V
authors.initials: CV
authors.lastname: Paya
authors.forename: D J
authors.initials: DJ
authors.lastname: McKean
authors.forename: D M
authors.initials: DM
authors.lastname: Segal
authors.forename: R A
authors.initials: RA
authors.lastname: Schoon
authors.forename: S D
authors.initials: SD
authors.lastname: Showalter
authors.forename: P J
authors.initials: PJ
authors.lastname: Leibson
mesh_terms: D000276:Adjuvants, Immunologic / Q000502:physiology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000502:physiology*; D001667:Binding, Competitive; D003432:Cross-Linking Reagents; D003602:Cytotoxicity, Immunologic; D006561:Herpes Simplex / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D018139:Simplexvirus / Q000276:immunology / Q000502:physiology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014779:Virus Replication
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D003432:Cross-Linking Reagents